Mycobacteria, particularly M. avium and M. tuberculosis, are a major cause of morbidity and mortality in AIDS. Because infection with these pathogens occurs mainly in tissues, bacilli may only intermittently be present in the circulation or in Other clinical specimens. The lack of a simple quantitative test which can be performed on easily-obtained specimens has hampered evaluation Of new regimens for prevention and treatment of mycobacterial disease, as well as delaying diagnosis and treatment. The stated intent of PA-96-068 is to encourage creative preclinical research emphasizing under-exploited facets of the basic biology, biochemistry, and pathophysiology of AIDS-related opportunistic infections, leading, in part, to development, preclinical validation, and standardization of rapid, non-invasive detection methods for early and specific diagnosis and for evaluation of responses to therapy. In response, this application will seek to determine the degree to which species-specific secreted mycobacterial antigens appear in the urine of infected hosts, and further, to determine whether detection of these products can be developed into sensitive, specific, and rapid tests for diagnosis and monitoring of treatment of mycobacterial disease.
The specific aims of this proposal are: 1) The identification and characterization by 1- and 2-D SDS-PAGE, western blot, and N-terminal amino acid sequence analysis, of species-specific antigens and/or epitopes in experimental and human M. avium and M. tuberculosis infection; and 2) Development, evaluation, and validation of quantitative assays for these antigens. Particular attention will be given to detection of two proteins in urine, as preliminary studies suggest that these antigens are abundantly produced, have species specific epitopes, and can be detected more readily in urine as compared to serum. This project may ultimately lead to the development of a novel assay which can be used clinically for diagnosis and management of latent and active mycobacterial infection in AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI041911-04
Application #
6319192
Study Section
AIDS and Related Research Study Section 5 (ARRE)
Program Officer
Laughon, Barbara E
Project Start
1997-09-01
Project End
2002-07-31
Budget Start
2000-08-15
Budget End
2002-07-31
Support Year
4
Fiscal Year
2000
Total Cost
$193,854
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
623946217
City
Newark
State
NJ
Country
United States
Zip Code
07107
Cheon, Seon-Hee; Kampmann, Beate; Hise, Amy G et al. (2002) Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 9:901-7
Wallis, R S; Phillips, M; Johnson, J L et al. (2001) Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. Antimicrob Agents Chemother 45:1302-4
Wallis, R S; Palaci, M; Vinhas, S et al. (2001) A whole blood bactericidal assay for tuberculosis. J Infect Dis 183:1300-3
Wallis, R S; Perkins, M D; Phillips, M et al. (2000) Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 161:1076-80
Wallis, R S; Patil, S; Cheon, S H et al. (1999) Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43:2600-6
Wallis, R S; Perkins, M; Phillips, M et al. (1998) Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. J Infect Dis 178:1115-21
Montesinos, M C; Gadangi, P; Longaker, M et al. (1997) Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med 186:1615-20